PE20142459A1 - Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre - Google Patents

Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre

Info

Publication number
PE20142459A1
PE20142459A1 PE2014001081A PE2014001081A PE20142459A1 PE 20142459 A1 PE20142459 A1 PE 20142459A1 PE 2014001081 A PE2014001081 A PE 2014001081A PE 2014001081 A PE2014001081 A PE 2014001081A PE 20142459 A1 PE20142459 A1 PE 20142459A1
Authority
PE
Peru
Prior art keywords
dpa
free acid
polyinsaturated
omega
fatty acids
Prior art date
Application number
PE2014001081A
Other languages
English (en)
Inventor
Timothy J Maines
Bernardus Nicolass Machielse
Bharat M Mehta
Gerald Wisler
Michael H Davidson
Peter Ralph Wood
Original Assignee
Omthera Pharmaceuticals Inc
Chrysalis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omthera Pharmaceuticals Inc, Chrysalis Pharma Ag filed Critical Omthera Pharmaceuticals Inc
Publication of PE20142459A1 publication Critical patent/PE20142459A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Materials For Photolithography (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE EN FORMA DE ACIDO LIBRE: EPA (ACIDO EICOSAPENTANOICO) EN UNA CANTIDAD DE ENTRE 50% (m/m) A 60% (m/m), DHA (ACIDO DOCOSAHEXANOICO) EN UNA CANTIDAD DE ENTRE 15% (m/m) A 25% (m/m) Y DPA EN UNA CANTIDAD DE NO MENOS DEL 1% (m/m). DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA HIPERTRIGLICERIDEMIA, PARA REDUCIR O PREVENIR LA RESISTENCIA A LOS INHIBIDORES DE LA AGREGACION PLAQUETARIA, ENTRE OTROS
PE2014001081A 2012-01-06 2013-01-04 Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre PE20142459A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261583796P 2012-01-06 2012-01-06
US201261664047P 2012-06-25 2012-06-25
US201261669940P 2012-07-10 2012-07-10
US201261680622P 2012-08-07 2012-08-07
US201261710517P 2012-10-05 2012-10-05
US201261713388P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
PE20142459A1 true PE20142459A1 (es) 2015-01-23

Family

ID=48744082

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001081A PE20142459A1 (es) 2012-01-06 2013-01-04 Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre

Country Status (34)

Country Link
US (5) US9050308B2 (es)
EP (2) EP3348262A1 (es)
JP (3) JP6399655B2 (es)
KR (2) KR102153143B1 (es)
CN (3) CN108524483A (es)
BR (1) BR112014016788A8 (es)
CA (1) CA2860512C (es)
CL (1) CL2014001803A1 (es)
CO (1) CO7061070A2 (es)
CY (1) CY1120663T1 (es)
DK (1) DK2800563T3 (es)
DO (1) DOP2014000159A (es)
EC (1) ECSP14012527A (es)
ES (1) ES2685703T3 (es)
HK (2) HK1202073A1 (es)
HR (1) HRP20181418T1 (es)
HU (1) HUE039659T2 (es)
IL (3) IL233517A (es)
IN (1) IN2014DN06125A (es)
LT (1) LT2800563T (es)
MX (1) MX358319B (es)
MY (1) MY165048A (es)
NZ (1) NZ626699A (es)
PE (1) PE20142459A1 (es)
PH (2) PH12014501553A1 (es)
PL (1) PL2800563T3 (es)
PT (1) PT2800563T (es)
RS (1) RS57777B1 (es)
RU (2) RU2018116572A (es)
SG (2) SG10201701004RA (es)
SI (1) SI2800563T1 (es)
UA (1) UA114615C2 (es)
WO (1) WO2013103902A1 (es)
ZA (1) ZA201405765B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
UA114615C2 (uk) * 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
RU2645075C2 (ru) 2012-05-07 2018-02-15 Омтера Фармасьютикалс, Инк. Композиции статинов и омега-3 жирных кислот
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
JP2016500055A (ja) * 2012-10-23 2016-01-07 ディーキン・ユニバーシティー トリグリセリドを低減させる方法
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9452151B2 (en) * 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
WO2015024055A1 (en) * 2013-08-20 2015-02-26 Deakin University Separation of omega-3 fatty acids
EP3738586A1 (en) 2013-10-30 2020-11-18 Patheon Softgels Inc. Enteric soft capsules comprising polyunsaturated fatty acids
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
CA2947741A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
SG11201610207WA (en) 2014-06-04 2017-01-27 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and use of same
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
WO2016069446A1 (en) * 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) * 2014-11-05 2016-05-12 Omthera Pharmaceuticals Inc. Methods of treatment
US20160192126A1 (en) * 2014-12-31 2016-06-30 Silver Spring Networks, Inc. System and method for tracking a device
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2016178066A1 (en) * 2015-05-01 2016-11-10 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
US10263794B2 (en) * 2016-05-19 2019-04-16 Linear Technology Corporation Maintain power signature controller at power interface of PoE or PoDL system
EP3454907B1 (en) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
GB201611920D0 (en) 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
WO2019034698A1 (en) 2017-08-15 2019-02-21 Evonik Technochemie Gmbh TABLET WITH HIGH ACTIVE INGREDIENT CONTENT OF OMEGA-3 FATTY ACID AMINO ACID SALTS
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
JP2022543283A (ja) 2019-08-08 2022-10-11 エボニック オペレーションズ ゲーエムベーハー 多価不飽和脂肪酸塩を製造するための下流処理
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
BR8803255A (pt) 1981-11-10 1990-02-06 Century Lab Inc Processo de extracao e purificacao de acidos graxos poli-insaturados de fontes naturais
JPS59157018A (ja) 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
JPS59225115A (ja) 1983-06-06 1984-12-18 Ota Seiyaku Kk 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル
JPS61126016A (ja) 1984-11-22 1986-06-13 Toagosei Chem Ind Co Ltd 不飽和脂肪酸を内相物としたマイクロカプセル
EP0347509A1 (en) 1988-06-21 1989-12-27 Century Laboratories Inc. A process of extraction and purification of polyunsaturated fatty acids from natural sources
CH669208A5 (fr) 1986-12-17 1989-02-28 Nestle Sa Procede de fractionnement en continu d'un melange d'acides gras.
US5243046A (en) 1986-12-17 1993-09-07 Nestec S.A. Process for the continuous fractionation of a mixture of fatty acids
ES2040847T3 (es) 1987-04-27 1996-07-16 Efamol Holdings Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
ZA885473B (en) 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
NL9201438A (nl) 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
EP0679057B1 (en) 1993-01-15 1999-08-18 Abbott Laboratories Structured lipids
AU676910B2 (en) 1993-04-29 1997-03-27 Norsk Hydro A.S Processes for chromatographic fractionation of fatty acids and their derivatives
JPH0753356A (ja) 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
US5767156A (en) 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
IT1264987B1 (it) 1993-12-14 1996-10-17 Prospa Bv Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
US5494684A (en) 1994-02-23 1996-02-27 Bar-Ilan University Plant protection from infection by Phytophthora infestans using fish oil
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
RU2127115C1 (ru) 1994-03-28 1999-03-10 Владимир Константинович Гаврисюк Смесь омега-3 полиненасыщенных жирных кислот
ES2131129T3 (es) 1994-05-09 1999-07-16 Nestle Sa Procedimiento para la preparacion de un concentrado de esteres de acidos grasos poliinsaturados.
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JPH08100191A (ja) * 1994-09-30 1996-04-16 Nisshin Flour Milling Co Ltd 高度不飽和脂肪酸またはそのエステルの精製方法
NL9401743A (nl) 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
GB2300807B (en) 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
WO1997039759A2 (en) 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JPH1095744A (ja) * 1996-09-20 1998-04-14 Nof Corp 高度不飽和脂肪酸又はそのアルキルエステルの製造方法
DE69622722T2 (de) 1996-11-20 2003-02-27 Nutricia Nv Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
GB9701705D0 (en) 1997-01-28 1997-03-19 Norsk Hydro As Purifying polyunsatured fatty acid glycerides
AU6184298A (en) 1997-02-25 1998-09-09 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
NO312973B1 (no) 1999-02-17 2002-07-22 Norsk Hydro As Lipase-katalysert forestring av marine oljer
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
JP2001054396A (ja) 1999-06-08 2001-02-27 Nippon Suisan Kaisha Ltd リパーゼによる高度不飽和脂肪酸含有油脂の製造方法
WO2001006983A2 (en) 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
NO310113B1 (no) 1999-08-11 2001-05-21 Norsk Hydro As Fremgangsmåte for utvinning av flerumettede fettsyrer fra ureakomplekser
WO2001015552A1 (en) 1999-08-30 2001-03-08 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
WO2001015702A1 (fr) 1999-08-31 2001-03-08 Chugai Seiyaku Kabushiki Kaisha Capsules molles
EP1106072B1 (en) 1999-12-10 2005-11-30 Loders Croklaan B.V. Palmitoleic acid and its use in foods
AU2634101A (en) 2000-01-06 2001-07-16 Martek Biosciences Corporation Therapeutic preparations of highly unsaturated fatty acids
EP1157692B1 (en) 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
EP1178103A1 (en) 2000-08-02 2002-02-06 Dsm N.V. Purifying crude pufa oils
KR20010008387A (ko) 2000-11-30 2001-02-05 이성권 결정화방법을 이용한 고순도 불포화지방산의 분리 정제 방법
DK1406641T3 (da) 2001-06-18 2009-05-04 Neptune Technologies & Bioress Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme
CN1197564C (zh) * 2001-09-30 2005-04-20 中国药品生物制品检定所 海狗油在制备治疗脂代谢紊乱药物中的应用
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB2385852A (en) 2002-02-27 2003-09-03 Rothamsted Ex Station Delta 6-desaturases from Primulaceae
AU2003218319A1 (en) 2002-03-22 2003-10-13 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
ITMI20020731A1 (it) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
NZ518504A (en) 2002-04-22 2005-05-27 Ind Res Ltd Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
NO319194B1 (no) 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004056370A1 (en) 2002-12-20 2004-07-08 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
EP1622467A1 (en) 2003-05-05 2006-02-08 Denofa AS Fish oils with an altered fatty acid profile, method of producing same and their use
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
WO2005005585A1 (ja) 2003-07-09 2005-01-20 J-Oil Mills, Inc. 長鎖高度不飽和脂肪酸を含む抗酸化油脂組成物
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US20080193549A1 (en) 2004-07-05 2008-08-14 Otago Innovation Limited Hoki Fish Liver Oil, Fractions Thereof And Therapeutic Uses
MX2007000813A (es) 2004-07-19 2007-06-05 Thia Medica As Composicion que comprende aceites de pescado y/o de planta y compuestos que comprenden entidades de acido graso no oxidable.
RU2394598C2 (ru) 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
WO2007130714A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
JP2008509154A (ja) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2007130713A1 (en) 2006-02-01 2007-11-15 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
NZ552390A (en) 2004-08-06 2010-01-29 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
US7829708B2 (en) 2004-09-08 2010-11-09 Chelsea Therapeutics, Inc. Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
DE102004062141A1 (de) 2004-12-23 2006-07-06 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Verfahren zur Herstellung eines Rohöls aus Gemischen von Mikroorganismen und Pflanzen, das so hergestellte Öl sowie die spezifischen Verwendungen des so hergestellten und gegebenenfalls zusätzlich raffinierten Öls
JP5503846B2 (ja) 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用
EP1858352B1 (en) 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
EP1861087A4 (en) 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
DE102005013779A1 (de) 2005-03-22 2006-09-28 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen
WO2006102896A2 (en) 2005-03-29 2006-10-05 Aalborg Universitet A process to concentrate ω3-pufa from fish oil by selective hydrolysis using cutinase immobilized on zeolite nay
KR100539357B1 (ko) 2005-04-11 2005-12-28 동부한농화학 주식회사 불포화 지방산의 제조방법
US20090203778A1 (en) 2005-05-04 2009-08-13 Morten Bryhn Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
EA200800225A1 (ru) 2005-07-01 2008-06-30 Мартек Байосайенсиз Корпорейшн Содержащий полиненасыщенные жирные кислоты маслопродукт и его применения и получение
US20070020340A1 (en) 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
EP1922065A4 (en) 2005-08-04 2009-11-11 Transform Pharmaceuticals Inc NEW FORMULATIONS WITH FENOFIBRATE AND A STATIN AND RELEVANT TREATMENT PROCESS
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
FR2896172B1 (fr) 2006-01-17 2008-10-10 Polaris Soc Par Actions Simpli Nouveau procede de stabilisation des acides gras polyinsatures et les compositions ainsi obtenus.
DE102006008030A1 (de) 2006-02-21 2007-08-23 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten Fettsäuren
AR059376A1 (es) 2006-02-21 2008-03-26 Basf Plant Science Gmbh Procedimiento para la produccion de acidos grasos poliinsaturados
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
US8003813B2 (en) 2006-06-27 2011-08-23 Pos Pilot Plant Corporation Process for separating saturated and unsaturated fatty acids
KR100684641B1 (ko) 2006-07-25 2007-02-22 주식회사 일신웰스 유지 조성물, 이를 함유하는 식품 및 건강보조식품
WO2008012329A2 (en) 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
KR100758664B1 (ko) 2006-08-16 2007-09-13 (주)케비젠 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품
CN101194913A (zh) * 2006-12-05 2008-06-11 张金生 治疗血脂偏高的天然海豹油浓缩生物制剂及其制备工艺
ES2604081T3 (es) 2007-01-10 2017-03-02 Dsm Nutritional Products Ag Microcápsulas que incluyen proteína de guisante
JP2010515773A (ja) 2007-01-16 2010-05-13 リライアント・ファーマシューティカルズ・インコーポレイテッド 非ステロイド系抗炎症薬およびオメガ−3脂肪酸を用いる治療ならびにその組合せ生成物
CN101663031A (zh) 2007-02-20 2010-03-03 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法
AU2008229604B2 (en) 2007-03-20 2013-05-30 Scf Pharma Inc. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
CA2685272A1 (en) 2007-04-26 2008-11-06 Patrick Adlercreutz A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof
WO2009009040A2 (en) 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
CA2694054C (en) 2007-07-25 2015-11-17 Epax As Omega-3 fatty acid fortified composition
JP5204776B2 (ja) 2007-07-30 2013-06-05 日本水産株式会社 Epa濃縮油およびdha濃縮油の製造方法
WO2009020406A1 (en) 2007-08-07 2009-02-12 Granate Seed Limited Methods of making lipid substances, lipid substances made thereby and uses thereof
WO2009028457A1 (ja) 2007-08-29 2009-03-05 Shinshu University 非アルコール性脂肪肝炎治療薬
DE102007055344A1 (de) 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
CN101969932A (zh) 2008-01-10 2011-02-09 武田药品工业株式会社 胶囊制剂
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
KR20110021886A (ko) 2008-05-15 2011-03-04 프로노바 바이오파마 노르지 에이에스 크릴 오일 처리 방법
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
PL2337857T3 (pl) 2008-10-02 2017-09-29 Gonzalez Ramon Ekstrakt z mikroalg zawierający 3-wielonienasycone kwasy tłuszczowe i sposób ekstrakcji oleju z mikroorganizmów
WO2010049954A1 (en) 2008-10-31 2010-05-06 Lipid Pharmaceuticals Ehf. Fatty acids for use as a medicament
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
CN101822651A (zh) * 2009-03-05 2010-09-08 Dpa工业公司 可咀嚼胶囊及其制备方法
CN110538148A (zh) 2009-03-09 2019-12-06 巴斯夫股份公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
ES2574136T5 (es) 2009-04-17 2019-08-30 Natac Pharma S L Composiciones ricas en ácidos grasos omega 3 con un bajo contenido en ácido fitánico
NO2424356T3 (es) 2009-04-29 2018-01-20
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PL2419114T5 (pl) 2009-05-01 2019-09-30 Uas Laboratories Llc Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej
ES2661217T3 (es) * 2009-06-15 2018-03-28 Amarin Pharmaceuticals Ireland Limited Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
IN2012DN02661A (es) 2009-09-01 2015-09-11 Catabasis Pharmaceuticals Inc
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2895477T3 (es) 2009-10-23 2022-02-21 Basf As Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos
RU2009145010A (ru) 2009-12-04 2011-06-20 Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) Композиция омега-3 и омега-6 полиненасыщенных жирных кислот
WO2011095284A1 (de) 2010-02-02 2011-08-11 Cognis Ip Management Gmbh Anreicherung von mehrfach ungesättigten fettsäuren
GB201006204D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
WO2011133610A1 (en) 2010-04-22 2011-10-27 E. I. Du Pont De Nemours And Company Method for obtaining polyunsaturated fatty acid-containing compositions from microbial biomass
US9476008B2 (en) 2010-06-25 2016-10-25 Epax As Process for separating polyunsaturated fatty acids from long chain unsaturated or less saturated fatty acids
US20140004186A1 (en) 2010-09-08 2014-01-02 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
US9145533B2 (en) 2010-09-24 2015-09-29 Pronova Blopharm Norge AS Process for concentrating omega-3 fatty acids
WO2012083034A1 (en) 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
WO2012087153A1 (en) 2010-12-23 2012-06-28 Marine Bioproducts As Enrichment of marine oils with omega-3 polyunsaturated fatty acids by lipase-catalysed hydrolysis
EP2476425B1 (en) 2011-01-14 2014-03-19 Visiotact Pharma Composition comprising OPC and Omega-3 for preventing and/or inhibiting the development of diabetic retinopathy
EP2675445A1 (en) 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
WO2012112511A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
CA2827577A1 (en) 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
JP2014505731A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患のリスク因子を治療するための、EPA、DHAおよびDPAを含むω3製剤
WO2012112902A1 (en) 2011-02-18 2012-08-23 Martek Biosciences Corporation Methods of preparing free polyunsaturated fatty acids
WO2012156986A1 (en) 2011-04-28 2012-11-22 Duragkar Nandakishore Jeevanrao Eicosapentaenoic acid (epa) as polyunsaturated free fatty acid in its directly compressible powder form and process of isolation thereof
CN102311868B (zh) 2011-04-29 2017-05-24 塞拉斯有限责任公司 一种无溶剂提取富含磷脂和中性油脂的磷虾油的方法
US8697676B2 (en) 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
EP2755646A4 (en) 2011-09-15 2015-06-10 Omthera Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO THROMBIA THERAPY
WO2013059669A1 (en) 2011-10-21 2013-04-25 Omthera Pharmaceuticals, Inc. Methods and compositions for treating or preventing attention deficit hyperactivity disorder
US9861605B2 (en) 2011-10-24 2018-01-09 Stable Solutions Llc Enriched injectable emulsion containing selected fatty acid triglycerides
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
CN109966279A (zh) 2012-03-30 2019-07-05 微团生物制药有限公司 ω-3脂肪酸酯组合物
RU2645075C2 (ru) 2012-05-07 2018-02-15 Омтера Фармасьютикалс, Инк. Композиции статинов и омега-3 жирных кислот
US20140194512A1 (en) 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2016069446A1 (en) 2014-10-28 2016-05-06 Omthera Pharmaceuticals Inc Methods for modulating plasma levels of lipoproteins
WO2016073335A1 (en) 2014-11-05 2016-05-12 Omthera Pharmaceuticals Inc. Methods of treatment
WO2016130417A1 (en) 2015-02-11 2016-08-18 Omthera Pharmaceuticals Inc Omega-3 fatty acid prodrug compounds and uses thereof
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres

Also Published As

Publication number Publication date
IL233517A0 (en) 2014-08-31
UA114615C2 (uk) 2017-07-10
US10117844B2 (en) 2018-11-06
BR112014016788A2 (pt) 2017-06-13
IL233517A (en) 2017-05-29
ZA201405765B (en) 2016-05-25
DOP2014000159A (es) 2014-12-15
ECSP14012527A (es) 2015-09-30
JP6399655B2 (ja) 2018-10-03
PH12015502307A1 (en) 2017-04-10
JP2020045358A (ja) 2020-03-26
US20150004224A1 (en) 2015-01-01
HUE039659T2 (hu) 2019-01-28
IN2014DN06125A (es) 2015-08-14
US9050309B2 (en) 2015-06-09
CO7061070A2 (es) 2014-09-19
BR112014016788A8 (pt) 2017-07-04
SG11201403805WA (en) 2014-08-28
IL266231B (en) 2020-08-31
EP2800563B1 (en) 2018-07-11
CA2860512C (en) 2019-02-05
US9050308B2 (en) 2015-06-09
SI2800563T1 (sl) 2018-11-30
CY1120663T1 (el) 2019-12-11
US20150320715A1 (en) 2015-11-12
CN107050457A (zh) 2017-08-18
IL252084B (en) 2019-05-30
RU2014128500A (ru) 2016-02-27
US20130177643A1 (en) 2013-07-11
IL266231A (en) 2019-06-30
MX358319B (es) 2018-08-14
US20130209556A1 (en) 2013-08-15
HRP20181418T1 (hr) 2018-11-30
PH12014501553B1 (en) 2014-10-08
KR20140135695A (ko) 2014-11-26
HK1202073A1 (en) 2015-09-18
WO2013103902A1 (en) 2013-07-11
EP3348262A1 (en) 2018-07-18
EP2800563A4 (en) 2015-06-17
DK2800563T3 (en) 2018-10-08
MY165048A (en) 2018-02-28
PH12014501553A1 (en) 2014-10-08
JP2015503590A (ja) 2015-02-02
PT2800563T (pt) 2018-11-07
US20190029985A1 (en) 2019-01-31
RU2018116572A (ru) 2018-10-23
CN108524483A (zh) 2018-09-14
JP2017214392A (ja) 2017-12-07
CA2860512A1 (en) 2013-07-11
NZ626699A (en) 2017-03-31
KR102153143B1 (ko) 2020-09-08
CN104321055A (zh) 2015-01-28
JP6626857B2 (ja) 2019-12-25
CL2014001803A1 (es) 2015-01-30
SG10201701004RA (en) 2017-04-27
KR20190119658A (ko) 2019-10-22
LT2800563T (lt) 2018-10-25
MX2014008309A (es) 2015-04-13
KR102153245B1 (ko) 2020-09-08
RS57777B1 (sr) 2018-12-31
ES2685703T3 (es) 2018-10-10
PL2800563T3 (pl) 2018-12-31
PH12015502307B1 (en) 2017-04-10
RU2664429C2 (ru) 2018-08-17
HK1251457A1 (zh) 2019-02-01
IL252084A0 (en) 2017-07-31
EP2800563A1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
PE20142459A1 (es) Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CL2016003041A1 (es) Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014.
CL2015002066A1 (es) Composiciones que incluye agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos.
BR112015006017A2 (pt) estabilização de sistemas de cápsulas em produtos de lavagem e outros produtos de limpeza
PE20141998A1 (es) Composiciones topicas que comprenden fipronilo y permetrina y sus metodos de uso
CL2013000379A1 (es) Composiciones de alimentacion de acuicultura que comprende una fuente de acido eicosapentaenoico (epa) y opcionalmente al menos una fuente de acido docosahexanoico; método para fabricar una composicion de alimentacion de acuicultura.
MX2015011767A (es) Composiciones de aceite crudo de algas.
NZ716341A (en) Glyceride composition
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
NZ734149A (en) Millicapsule formulations comprising polyunsaturated free fatty acids
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
BR112015028696A2 (pt) composições de óleo estruturadas
BR112014017048A8 (pt) emulsão orgânica compreendendo dha e epa
BR112015022117A2 (pt) precursor da composição cosmética, composição cosmética para a aplicação tópica, método para a administração de um agente cosmético sólido e amida de triciclodecano
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
BR112015008195A2 (pt) composição de triglicerídeos e dispositivo elétrico
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
CL2018000753A1 (es) Gel hidrófobo basado en vitamina e libre de productos de silicona para aplicación tópica
AR097517A1 (es) Composiciones antitranspirantes con hidroxialquilurea
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
AR095401A1 (es) Método y composición del tratamiento de las semillas de canola
CR20140350A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre

Legal Events

Date Code Title Description
FG Grant, registration